Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...

Nykode Therapeutics (VACBF) announced last night that it has received notification from Genentech, a member of the Roche (RHHBY), of its decision to terminate the collaboration and licensing ...

Genentech, a member of the Roche (RHHBY), announced that it will present more than 40 abstracts across nine blood disorders at the 66th ...

“More selective inhibitors may be safer.” Genentech started working on PI3K nearly two decades ago, focusing mainly on an isoform that is often dysregulated in a common form of breast ...

UCB granted Roche and its biotech unit Genentech an exclusive worldwide license to bepranemab, then called UCB0107, in 2020 as part of a deal worth around $2 billion in milestones. The agreement ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

In 2021, the company teamed up with Roche’s subsidiary Genentech on T cell therapy development – a five-year agreement with a potential value exceeding $3bn. However, Genentech walked away ...